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and the Nashville Veterans Affairs Hospital from 1994 to 2002. 
Central pathologic review was performed on biopsies from 12 
patients. All but two patients presented with advanced stage at 
diagnosis. Median age at transplant for the autologous and allo- 
geneic groups was 53.5 and 49.5 years, respectively. A total of 17 
autologous, 1 syngeneic, and 6 alIogeneic transplants were per- 
formed. Five patients underwent autologous transplantation in 
first complete remission. Results: In the autologous group, median 
overall survival was 4.75 years (95% C.I. 3.7 to 5.8y) and median 
survival from transplant was 2.5 years (95% C.I. 1.3 to 3.7y). The 
Kaplan-Meier estimate of 5-year overall survival was 41% (95% 
C.I. 10% to 72%). in the allogeneic group, 4 patients have died. 
Post-transplant survival ranged from 13 days to 3.4 years. 
Chemosensitivity, defined as the maintenance of at least a partial 
response after the last chemotherapy regimen until the date of 
autologous transplant, was associated with improved overall sur- 
vival by log-rank analysis (p=.0005). For these 13 patients the esti- 
mated 5-year overall survival was 56% (95% C.I. 17% to 95%). 
Post-transplant survival was also significantly prolonged in this 
group (median 3.5 years vs. 319 days, p<.0001, 95% C.I. 1.6 to 
5.4y vs. 26d to 1.Ty). Conclusions: The longest overall survival 
occurred in patients with chemosensitive disease who received 
autologous transplantation. Neither the use of total-body irradia- 
tion, fewer than four pre transplant chemotherapy regimens, nor 
transplant in first remission was found to predict for improved 
survival. Although the confidence intervals are wide, these results 
support he hypothesis that patients with chemosensitive mantle 
cell lymphoma may realize a significant survival benefit from 
autologous transplantation. 
155 
EX VIVO ACTIVATION AND EXPANSION OF T CELLS FROM THE 
PERIPHERAL BLOOD OF MULTIPLE MYELOMA PATIENTS USING THE 
XCELLERATE TM PROCESS 
F~'oblich, M. W. 1¢ 17escio, R. 2; Be're~Tsolz, J. 2; Ra~w~z~'se~, A. ;t~da~msz, 
D3; Roehrs, H.t; ~VIa'rkha~, E J; Gree~z, CJ; Be~'e~zso~z, R.ff 3; Bo~yha- 
di, 3/i. ~ 1. X~te Ther, tpies, Seattle, fu, q; 2. Cedars-Signal Medical Ce~- 
te~', Los A*zgeles, CA. 
Previous studies in multiple lnyeloma have demonstrated a 
significant association between survival and baseline l vels of 
T cells prior to chemotherapy (Kay et al., Blood 200l) as well 
as lymphocyte counts 15 days following autologous transplan- 
tation (Porrata et al., Blood 2001). Therefore, infusion of large 
numbers of T cells post transplant may improve clinical 
results. We have developed the Xcellerate TM process for the ex 
vivo activation and expansion of T cells using immobilized 
anti-CD3 and anti-CD28 antibodies covalently linked to mag- 
netic beads (Dynabeads® M-450 CD3/CD28 T). Twenty-two 
expansions have been conducted to date using samples from 
multiple myeloma patients who have received avariety of prior 
therapies. The number of T cells increased a mean of 404 fold 
foIlowing an 8-14 day culture process. Purity and viability of T 
ceils post-Xcellerate averaged 97% and 96%, respectively. The 
CD4/CD8 ratio increased from 1.3to 2.1 during the course of 
culture. Significant upregulation of key surface/effector mole- 
cules, including CD25 (IL-2 receptor) and CD154 (CD40 fig- 
and) occurred. Moreover, we have developed a flow cytome- 
try-based assay system for evaluating residual plasma cells in 
the final T cell product. Using analysis of surface marker 
expression, including CD38, CD138, CD45 and CD56, we 
have been unable to detect any plasma cells in the final prod- 
uct within the limits of detection of'the assay (~0.01%). Based 
upon these data, we have initiated a clinical trial to evaluate 
the activity of Xcellerated T Cells in patients with multiple 
myeloma, who are undergoing an autologous stem cell trans- 
plantation. Following induction chemotherapy, patients will 
undergo a leukapheresis to collect T cells for the Xcellerate 
Process. Patients will then undergo stem cell mobilization and 
collection, follwed by high dose chemotherapy with Melpha- 
lan. Patients will then receive a stem cell infusion, followed 
three days later by an infusion of 5-10 x 10 l° autologous 
Xcellerated T Cells. 
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A CLINICAL TRIAL OF GENE TRANSFER TO BONE MARROW CD34+ 
CELLS FROM ADA-DEFICIENT SCID SUBJECTS 
Koh~, D.B.2; Podsateoff G. z, ETzgel, B.C.:; Cavbomrro, D. e, 
&71og'ovzewska, M. 2; C'hoi, C. e; ~/lltzt[, L.1; Sc/]zt'vTzlmz, S. t; Dul~bar, 
C.I; Weir*berg, K.I.:; CmTdotti, F. 1 1. ChildT"eTzs Hospital Los 
A1zgeles/I'~2,ck USC School of ~ledichze, Los A1zgeles, CA; 2. Natiolzal 
Hzt1~lalz GeJ~om, e Resem'eh IiTstimte/NIH, Bethesda, MD. 
Gene transfer to hematopoietic stem ceils (HSC) may provide 
new treatments for genetic diseases of blood cells that are more 
effective or safer than current approaches using allogeneic trans- 
plantation. Retroviral vectors have been used most often to obtain 
stable gene transfer to HSC and there has been incremental 
progress in the design and production of retroviral vectors and in
the methods used to transduce human HSC. Nevertheless, the 
percentages of reconstituting stem cells that can be transduced in
the clinical setting have been too low to be of benefit in most dis- 
orders (e.g.0.01-1%). However, immune deficiencies, including 
severe combined immune deficiency (SCID) and AIDS, may be 
benefited by gene transfer levels in that range, because the gene- 
modified T lymphocytes may have a selective production or sur- 
vival advantage, compared to the non-corrected cells. The high 
rate of immune reconstitution (90%) in subjects with XSCID 
treated with gene transfer firmly demonstrates the benefits of this 
approach. However, the development of a monoclonal T lympho- 
proliferation in one subject underscores the potential toxicities of 
this approach. We are performing a clinical trial for subjects with 
ADA deficient SCID. Four subjects (ages 4-20 years) have been 
enrolled and have undergone the procedure of bone marrow har- 
vest, CD34+ cell isolation, retroviral-mediated ADA gene trans- 
duction, and cell re-infizsion, without serious adverse vent. The 
subjects did not receive marrow cytoreductive conditioning before 
the cell re-infusion and have all continued to receive PEG-ADA 
enzyme replacement therapy. Follow-up times (thur 10/15/02) are 
currently 13, 12, 9 and 8 months. The transferred ADA gene has 
been detected in peripheral blood samples of all subjects, at fre- 
quencies of between 0.001-3%. A staged withdrawal of enzyme 
replacement may begin after the first year. Clinical trials need to 
be performed to determine the relative benefits and risks of gene 
transfer to HSC as a treatment for SCID, compared to approaches 
using allogeneic HSCT. 
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THROMBOTIC MICROANGIOPATHY (TMA), ENCEPHALITIS, AND 
SEIZURES DUE TO HUMAN HERPES VIRUS-6 (HHV-6) REACTIVATION 
IN AN ADULT RECEIVING HIGH-DOSE MELPHALAN WITH AUTOLO- 
GOUS PERIPHERAL STEM CELL TRANSPLANTATION (ASCT) 
Bel~bvd, A.3/I.S; Myles, O.S; Myt.,a~zd, R.C3; ~aJzg,, j.3; Magi~l, A.:, 
~'~'?lsele*zko, J.K. 1 1. ~{~dter Reed AJvzly Medical Ce~zte,-, ~P~lshi*gto*~, 
DC; 2. FValte~" Reed ,*ttwt~ bzstimte of Research, Silver Sprhlg, 3/ID; 
3. Uzzifo*vzled SeJvices U~zfversity, Bethesda, 3lID. 
Herein, we report an adult with TMA associated with HHV-6 
reactivation occurring after ASCT. To our knowledge, this repre- 
sents the first such case in an adult. A 58-year-old female with 
Stage IIIA IgGK multiple myeloma received VAD for 4 cycles fol- 
lowed by" melphalan (200 mg/m2) with ASCT. She was discharged 
on D+16 with resolution of her transplant related toxicities. On 
D+22 she was readmitted with dyspnea, rash, and fever (105 F). 
Despite antibacterial nd antifungal therapy, worsening dyspnea 
and hypotension prompted ICU transfer. Five days later she 
developed TMA and therapeutic plasma exchange (TPE) was ini- 
tiated. Oaa D+28 mental status (MS) changes developed. Head CT 
and EEG were negative. Lumbar puncture (LP) revealed a CSF 
protein of 74. On D+32, a generalized seizure occurred. TPE was 
co~atinued without improvement in thrombocytopenia or her MS 
despite normalization of her LDH, haptoglobin and total biliru 
bin. She required intubation for a depressed MS and another 
seizure. An EEG was consistent with an encephalopathy, and a 
brain MRI showed a right temporal lobe infarct. Serum PCR was 
negative for CMV but positive for HHV-6. Repeat LP demon- 
strated aprotein of 597, a negative CMV antibody, and CSF PCR 
for HSV1, HSV2 were negative but strongly positive for HHV-6 
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(1400 DNA copies/mL), prompting foscarnet initiation. Her MS 
greatly improved after the first week of antiviral therapy. Serum 
HHV-6 PeR became negative and a LP on D+53 revealed a nor- 
mal protein and CSF PCR for HHV-6 had decreased to 110 DNA 
copies/mL. She was changed to maintenance valganciclovir and 
TPE was tapered and discontinued after remittance of her TMA 
and normalization of her MS. hnportantly, HHV-6 reactivation 
must be considered in adult patients undergoing ASCT who 
develop encephalopathy, fevers of unknown origin, rash, or TMA. 
An aggressive pursuit of this diagnosis in the appropriate clinical 
setting is critical given its often fuhninant course in immnnosup- 
pressed patients who are left untreated. 
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AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN MULTIPLE 
MYELOMA (MM): ACHIEVEMENT OF CR IS ASSOCIATED WITH 
IMPROVED SURVIVAL 
Kmnar, L/; Kochupillai, ~U; Ga77essan, K~ 1. ALL India bzstitute of
k/ledical ScieJlces, Neu, Delhi, Delhi, II~dia; 2. All flzdia ITzstitztte of 
Medical Sciences, Nezz, Delhi, Delhi, India; 3. All India b~stitute of 
k/leclical Sciences, New Delhi, Delhi, imtia. 
Background : HD-CT  with ASCT is currently used in the treat- 
meat (Tt) of patients (Pts) with advanced MM.  Methods : 50 Pts 
(median age-52 years, range, 26-65) with advanced MM under- 
went T t  with HD melphalan with ASCT (BM -7, PB -43). M:F : 
35:15. All Pts initially had received CT, mean no of CT  cycles 
9.38 (range, I- 36). 30/50 (60%) patients had evidence of chemo- 
sensitive disease at transplant (Tx). Mean interval from diagnosis 
to Tx was 17.5 months (range, 3 to 129). Median no of MNC 
infused was 4. 86 xl0(8)/kg (range, 2 - 10.48). Results : Post -Tx, 
43 / 50 Pts engrafted; median no of days to engraft  (ANC 
(>g00/cmm) was 12 days (range, 9 - 24) & to achieve platelet 
transfusion independence (>20 K) was 13 days (range, 8 - 36). 
Grade III-IV oral mucositis was major non-haematologic toxicity. 
Following Tx, 78% of Pts responded; CR - 29 (58)%, & PR - 
20%. CR rate was higher for Pts with chemo-sensitive dis. ; 20/26 
Pts with PR at Tx achieved CR vs 5/20 Pts with persistentJrefrac- 
to W dis., p<.01. Post Tx, Pts received interferon-alfa (3 mU 3/wl 0 
for one year. Currently, 34/43 Pts (79%) are alive, 17 (39.5%) dis- 
ease-free, 9(21%) Pts have died ; 8 of progressive dis. & 1 of unre- 
lated cause. The  median FU for the whole group is 26 mon. 
(range, 1-144 nmnths). Estimated OS & PFS at 55 months is 58% 
& 34%, respectively. Low Hb (<10g%) (p<.003) & stage B dis. at 
diagnosis affected the survival adversely. Chemo-sensi t ive 
dis.(p<.008) at Tx and achievement of CR post - Tx (<.0001) were 
associated with significantly ilnproved sm-vival. Conclusions: HD 
melphalan with ASCT is an effective Tt  for advanced myeloma .
Achievement of CR is associated with improved survival. 
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REQUIRING MORE THAN TWO APHERESIS PROCEDURES IMPACTS 
ADVERSELY ON OUTCOME OF AUTOLOGOUS PERIPHERAL BLOOD 
STEM CELL TRANSPLANTATION 
Nieder, M.L.; k/lcCrae, E.; Fisher, V.L.; Fox, R.; Creger, R.; Lazavas, 
H.M., O'RioJ'&m, M. Case HZeste'rn Reserve University, Clevelamt, OH. 
Despite improvements in transplantation co-incident with the 
switch from marrow to blood, there remain obstacles to success 
(early relapse, failure to mobilize stenr cells). We reviewed our 
extensive 4 year experience to identify predictive factors for suc- 
cessful engraftment and survival. We wanted to determine if cer- 
tain difficulties encountered uring PBSC acquisition via aphere- 
sis had any affect on eventual engraftment after transplantation. 
We performed 790 apheresis procedures on 274 patients from 
1998-2001 (age range 7 months-69 years). The  majority of 
patients were mobilized with chenmtherapy and GCSF. However, 
a small number of patients received a combination of GM-CSF 
and G-CSF prior to PBSC collection. Of the entire group, 231 
patients (85%) eventually underwent transplantation. 7.3% of the 
patients were not transplanted because of unsuccessful mobiliza- 
tion/steln cell collection. Patients most conmmnly underwent 
transplantation as therapy for leukemia, breast cancer, Hodgldns 
and NonHodgkins Lymphoma and multiple myeloma. Patients 
who needed to undergo only 1 or 2 apheresis procedures (as com- 
pared to those needing 3 or more) had earlier engraftment of 
WBC and platelet counts and fewer infectious complications. 
These data suggest that patients who require more than two 
apheresis procedures prior to autograft should be considered at 
increased risk for complications during transplantation. Perhaps 
information regarding this increased risk should be incorporated 
into patient pre-transplant discussions and consent. 
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ENGRAFTMENT SYNDROME IN AUTOLOGOUS TRANSPLANTATION: A 
FUNCTION OF CD34+ CELL DOSE 
Dmlato, ~I.L.; Saliba, R.k/l.; Aleman, A.; Ippol#i, C.; Gershemon, D.; 
Betha,icow-t, D.; CTaampli,z, R. The University ofTexas k/I.D. Amler- 
solz Cancer Cente*', Hoaston, 7P~(. 
Engraftment syndrome (ES) has been described in the autologous 
transplant setting. Our aim was to determine factors predictive of 
ES in a uniform population. We have analysed 101 patients with 
advanced ovarian cancer receiving high-dose topotecan, melphalan 
and cyclophosphamide with autologous tem cell transplantation. 
Engraftment fever (EF) was the only component of ES observed in 
this group and was defined as onset of ever > 38 ° C within 3 days 
pre and 4 days post engrafnnent. Patients with fever starting prior to 
that or associated with an infection were considered unevaluable (18 
patients). The median age was 50 y (21-67y). The median time to 
ARC >0.5x109 was 9 days (8-11) and to platelets > 100xl09 was 15 
days (10-322). There were no transplant-related deaths. Of  the 83 
evaluable patients 37 (45%) had engraftment fever (38 ° - 39 ° C). 
These patients had received asignificantly higher number of CD34+ 
cells/kg (median 7.7 vs 10.1) p=0.01. Twenty patients (54%) with 
engraftment fever had peripheral blood blasts in the engraftment 
period compared to 13 % for patients without fever p<0.001.54% of 
patients with engraftment fever received methylprednisolone 
emperically, mostly lmg/kg (range 0.5-6.5 mg/kg). Age, prior ther- 
apy, and regimen-related to,city were not associated with a higher 
incidence of EF. The presence of EF had no impact on survival or 
progression-free survival. In conclusion, patients receiving >8- 
10xl 06 CD34+ cells/kg are at increased risk of developing engraft- 
ment fever and ma W will present with circulating blasts on engraft- 
nrent. Whether steroids are advisable remains to be determined. 
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THE EFFECT OF GLUTAMINE ON DISEASE PROGRESSION IN MULTIPLE 
MYELOMA (MM) PATIENTS RECEIVING HIGH-DOSE MELPHALAN 
Crook, if.L; H~lsale1~ko, if.I(.; Myhamt, R.C. H~dter Reed Alvny3/led- 
k'al Ce~ter, lT/ashiJ~gto~z, DC. 
Mucositis, a frequent complication of high-dose therapy, is asso- 
ciated with major morbidity and mortality. Glutamine is one 
agent hat has been shown to protect he gastro-intestinal epitheli- 
um from the toxic effects of chenmtherapy. Although oral gluta- 
mine has been used successfully to prevent transplant related 
mucositis, the potential for glutamine mediated tunmr protection 
has not been systematically investigated. In order to identify any 
possible tumor protective ffect of glutamine in high-dose thera- 
py, we performed a retrospective review of consecutive patients 
who received high-dose therapy with melphalan (200 rag/m2) for 
MM either with or without glutamine. Between July 1997 and 
August 2002, 41 patients were treated at our institution. The first 
17 patients did not receive glutamine prophylaxis. In July 2000, we 
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